Leerink Partners将福泰制药的投资评级从市场表现级上调至跑赢大盘级,同时将目标价从458美元下调至456美元。
Leerink Partners将福泰制药的投资评级从市场表现级上调至跑赢大盘级,同时将目标价从458美元下调至456美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.